Excretion and toxicity of gold-iron nanoparticles

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 3, 2013, Pages 356-365

  Jenkins, James T ^a   Halaney, David L ^a,b   Sokolov, Konstantin V ^c,d   Ma, Li L ^c   Shipley, Heather J ^e   Mahajan, Smridhi ^a   Louden, Christopher L ^a   Asmis, Reto ^a   Milner, Thomas E ^c   Johnston, Keith P ^c   Feldman, Marc D ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c The University of Texas at Austin   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e The University of Texas at San Antonio   (United States)

Author keywords

Biodegradation; Excretion; Gold nanoparticles; Iron oxide; Toxicity

Indexed keywords

CLINICAL APPLICATION; CLUSTERING DESIGN; EXCRETION; GOLD CONCENTRATION; GOLD NANOPARTICLES; IRON OXIDE NANOPARTICLE; LYSOSOMAL DEGRADATION; REDUCED TOXICITY;

BIODEGRADATION; IRON OXIDES; MAMMALS; METAL NANOPARTICLES; PHYSIOLOGY; TISSUE; TOXICITY;

GOLD;

GOLD NANOPARTICLE; IRON OXIDE; NANOPARTICLE; NANOROSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL HUSBANDRY; ARTICLE; BIODEGRADATION; BLOOD ANALYSIS; CELL CULTURE; CONTROLLED STUDY; DRUG EXCRETION; DRUG SYNTHESIS; IN VIVO STUDY; LIGHT SCATTERING; MACROPHAGE; MOUSE; NANOTECHNOLOGY; NONHUMAN; WILD TYPE;

ACIDS; ANIMALS; CELLS, CULTURED; GOLD; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; IRON; LIGHT; MACROPHAGES; METAL NANOPARTICLES; MICE; MICE, INBRED C57BL; SCATTERING, RADIATION; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET; TIME FACTORS; TOXICITY TESTS;

MURINAE; MUS;

EID: 84875503367     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.08.007     Document Type: Article

References (48)

1. Aillon K.L., Xie Y., El-Gendy N., Berkland C.J., Forrest M.L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 2009, 61:457-466.
2. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 2011, 40:1647-1671.
3. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine-UK 2008, 3:703-717.
4. Lewinski N., Colvin V., Drezek R. Cytotoxicity of nanoparticles. Small 2008, 4:26-49.
5. Fadeel B., Garcia-Bennett A.E. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 2010, 62:362-374.
6. Boisselier E., Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38:1759-1782.
7. Balasubramanian S.K., Jittiwat J., Manikandan J., Ong C.N., Yu L.E., Ong W.Y. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 2010, 31:2034-2042.
8. Alkilany A.M., Murphy C.J. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?. J Nanopart Res 2010, 12:2313-2333.
9. Almeida J.P.M., Chen A.L., Foster A., Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine-UK 2011, 6:815-835.
10. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Ipe B.I., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
11. Cho W.S., Cho M., Jeong J., Choi M., Han B.S., Shin H.S., et al. Size-dependent tissue kinetics of PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 2010, 245:116-123.
12. Wang L., Li Y.F., Zhou L., Liu Y., Meng L., Zhang K., et al. Characterization of gold nanorods in vivo by integrated analytical techniques: their uptake, retention, and chemical forms. Anal Bioanal Chem 2010, 396:1105-1114.
13. Semmler-Behnke M., Kreyling W.G., Lipka J., Fertsch S., Wenk A., Takenaka S., et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008, 4:2108-2111.
14. Fent G.M., Casteel S.W., Kim D.Y., Kannan R., Katti K., Chanda N., et al. Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine. Nanomedicine 2009, 5:128-135.
15. Hirn S., Semmler-Behnke M., Schleh C., Wenk A., Lipka J., Schäffler M., et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011, 77:407-416.
16. Sadauskas E., Danscher G., Stoltenberg M., Vogel U., Larsen A., Wallin H. Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine 2009, 5:162-169.
17. Goel R., Shah N., Visaria R., Paciotti G.F., Bischof J.C. Biodistribution of TNF-α-coated gold nanoparticles in an in vivo model system. Nanomedicine-UK 2009, 4:401-410.
18. Lankveld D.P.K., Rayavarapu R.G., Krystek P., Oomen A.G., Verharen H.W., van Leeuwen T.G., et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine-UK 2011, 6:339-349.
19. Niidome T., Yamagata M., Okamoto Y., Akiyama Y., Takahashi H., Kawano T., et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 2006, 114:343-347.
20. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J.A.M., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
21. Niidome T., Akiyama Y., Yamagata M., Kawano T., Mori T., Niidome Y., et al. Poly(ethylene glycol)-modified gold nanorods as a photothermal nanodevice for hyperthermia. J Biomater Sci 2009, 20:1203-1215.
22. Tam J.M., Tam J.O., Murthy A., Ingram D.R., Ma L.L., Travis K., et al. Controlled assembly of biodegradable plasmonic nanoclusters for near-infrared imaging and therapeutic applications. ACS Nano 2010, 4:2178-2184.
23. Sapozhnikova V., Willsey B., Asmis R., Wang T., Jenkins J.T., Mancuso J.J., et al. Use of near-infrared luminescent gold nanoclusters for detection of macrophages. J Biomed Opt 2012, 17:026006.
24. Wang T., Mancuso J.J., Sapozhnikova V., Dwelle J., Ma L.L., Willsey B., et al. Dual-wavelength multifrequency photothermal wave imaging combined with optical coherence tomography for macrophage and lipid detection in atherosclerotic plaques using gold nanoparticles. J Biomed Opt 2012, 17:036009.
25. Ma L.L., Feldman M.D., Tam J.M., Paranjape A.S., Cheruku K.K., Larson T.A., et al. Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy. ACS Nano 2009, 3:2686-2696.
26. Bennett B. Isolation and cultivation in vitro of macrophages from various sources in the mouse. Am J Pathol 1966, 48:165-181.
27. Davenas E., Poitevin B., Benveniste J. Effect on mouse peritoneal macrophages of orally administered very high dilutions of silica. Eur J Pharmacol 1987, 135:313-319.
28. Kunzmann A., Andersson B., Thurnherr T., Krug H., Scheynius A., Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011, 1810:361-373.
29. Franca A., Aggarwal P., Barsov E.V., Kozlov S.V., Dobrovolskaia M.A., González-Fernández Á. Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine-UK 2011, 6:1175-1188.
30. Shen T., Weissleder R., Papisov M., Bogdanov A., Brady T.J. Monocrystalline iron oxide nanocompounds (Mion): physicochemical properties. Magn Reson Med 1993, 29:599-604.
31. Sonavane G., Tomoda K., Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 2008, 66:274-280.
32. Xie J., Zheng Y., Ying J.Y. Protein-directed synthesis of highly fluorescent gold nanoclusters. J Am Chem Soc 2009, 131:888-889.
33. Lin C.J., Yang T., Lee C., Huang S.H., Sperling R.A., Zanella M., et al. Synthesis, characterization, and bioconjugation of fluorescent gold nanoclusters toward biological labeling applications. ACS Nano 2009, 3:395-401.
34. Gobin A.M., Lee M.H., Halas N.J., James W.D., Drezek R.A., West J.L. Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett 2007, 7:1929-1934.
35. Skotland T., Iversen T., Sandvig K. New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging. Nanomedicine 2010, 6:730-737.
36. Graham G.G., Whitehouse M.W., Bushell G.R. Aurocyanide, dicyano-aurate (I), a pharmacologically active metabolite of medicinal gold complexes. Inflammopharmacology 2008, 16:126-132.
37. 2+ entry into and subsequent suicidal death of erythrocytes. Toxicology 2008, 244:271-279.
38. Wiwanitkit V., Sereemaspun A., Rojanathanes R. Effect of gold nanoparticles on spermatozoa: the first world report. Fertil Steril 2009, 91:e7-e8.
39. Sereemaspun A., Rojanathanes R., Wiwanitkit V. Effect of gold nanoparticle on renal cell: an implication for exposure risk. Ren Fail 2008, 30:323-325.
40. 55clusters. Chem Soc Rev 2008, 37:1909-1930.
41. Cho W.S., Kim S., Han B.S., Son W.C., Jeong J. Comparison of gene expression profiles in mice liver following intravenous injection of 4 and 100 nm-sized PEG-coated gold nanoparticles. Toxicol Lett 2009, 191:96-102.
42. Zhang X.D., Wu D., Shen X., Liu P.X., Yang N., Zhao B., et al. Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int J Nanomed 2011, 6:2071-2081.
43. Cho W.S., Cho M., Jeong J., Choi M., Cho H.Y., Han B.S., et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 2009, 236:16-24.
44. Chen Y.S., Hung Y.C., Liau I., Huang G.S. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res Lett 2009, 4:858-864.
45. Terentyuk G.S., Maslyakova G.N., Suleymanova L.V., Khlebtsov B.N., Kogan B.Y., Akchurin G.G., et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J Biophoton 2009, 2:292-302.
46. Weissleder R., Stark D.D., Engelstad B.L., Bacon B.R., Compton C.C., White D.L., et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 1989, 152:167-173.
47. Bourrinet P., Bengele H.H., Bonnemain B., Dencausse A., Idee J.M., Jacobs P.M., et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 2006, 41:313-324.
48. DeMerlis C.C., Schoneker D.R. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol 2003, 41:319-326.